Fig. 3: ICD-based DC vaccines provide significant protective immunity against glioma.
A Experimental setup for the prophylactic vaccination of mice with DC-based vaccines loaded with GL261 cells treated with PS-PDT (PS at a dose of 1.4 µM). As controls, we used DC-based vaccines loaded with GL261 cells subjected to F/T cycles or treated with 2.0 µM MTX or mire were injected with PBS. The mice were injected on days 0 and 7, and seven days after the last vaccination they were intracranially injected with viable GL261 cells using stereotactic coordinates. B The curve represents the survival of mice in the four treatment groups of 6–7 mice per group for up to 24 days. Statistical significance was determined by the Mantel-Cox logarithmic test, *p < 0.01. C Diffusion-weighted tomography images for determining tumor volume (n = 6–7 per group). Statistical significance was determined by unpaired Mann–Whitney U test, *p < 0.05. D, E Temporal progression of neurological deficits in mice treated as described in (A). The neurological status of the mice for up to day 22 after intracranial tumor inoculation. The percentage of mice after intracranial tumor inoculation in the DC + PS-PDT or DC + MTX group showed a significant difference in the degree of neurological alterations (grades 0–4); n = 6–7 per group; *p < 0.01, a statistically significant difference from the PBS group; #statistically significant difference from the F/T group; Wilcoxon test.
